US Patent

US11299500 — Crystalline form of lorlatinib free base hydrate

Composition of Matter · Assigned to Pfizer Inc · Expires 2038-10-04 · 12y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a specific crystalline form of the lorlatinib free base hydrate, known as Form 24.

USPTO Abstract

This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base hydrate (Form 24). This invention also relates to pharmaceutical compositions comprising Form 24, and to methods of using Form 24 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.

Drugs covered by this patent

Patent Metadata

Patent number
US11299500
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-10-04
Drug substance claim
Yes
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.